Generex Biotechnology Corporation Price Chart
Generex Biotechnology Corporation GB8A.SG Financial and Trading Overview
Generex Biotechnology Corporation stock price | 0.02 EUR |
Previous Close | 0.02 EUR |
Open | 0.05 EUR |
Bid | 0.0027 EUR x 0 |
Ask | 0.07 EUR x 0 |
Day's Range | 0.009 - 0.05 EUR |
52 Week Range | 0.009 - 0.33 EUR |
Volume | 219.97K EUR |
Avg. Volume | 6.84K EUR |
Market Cap | 2.37M EUR |
Beta (5Y Monthly) | -0.480474 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.354 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
GB8A.SG Valuation Measures
Enterprise Value | 23.55M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 3.4195294 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 33.992 |
Enterprise Value/EBITDA | -0.707 |
Trading Information
Generex Biotechnology Corporation Stock Price History
Beta (5Y Monthly) | -0.480474 |
52-Week Change | -93.76% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.33 EUR |
52 Week Low | 0.009 EUR |
50-Day Moving Average | 0.05 EUR |
200-Day Moving Average | 0.13 EUR |
GB8A.SG Share Statistics
Avg. Volume (3 month) | 6.84K EUR |
Avg. Daily Volume (10-Days) | 28.4K EUR |
Shares Outstanding | 118.45M |
Float | 116.43M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.022% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor | 7:5 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | July 31, 2020 |
Most Recent Quarter (mrq) | April 30, 2021 |
Next Fiscal Year End | July 31, 2021 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -4952.48% |
Gross Margin | 48.23% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -43.84% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 692.76K EUR |
Revenue Per Share (ttm) | 0.007 EUR |
Quarterly Revenue Growth (yoy) | -95.89% |
Gross Profit (ttm) | 2.08M EUR |
EBITDA | -33303532 EUR |
Net Income Avi to Common (ttm) | -37261844 EUR |
Diluted EPS (ttm) | -0.354 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.68M EUR |
Total Cash Per Share (mrq) | 0.01 EUR |
Total Debt (mrq) | 10.6M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.039 |
Book Value Per Share (mrq) | -0.484 |
Cash Flow Statement
Operating Cash Flow (ttm) | -2368270 EUR |
Levered Free Cash Flow (ttm) | 9.56M EUR |
Profile of Generex Biotechnology Corporation
Country | Germany |
State | FL |
City | Miramar |
Address | 10102 USA Today Way |
ZIP | 33025 |
Phone | 416 364 2551 |
Website | https://generex.com/index.html |
Industry | |
Sector(s) | |
Full Time Employees | 15 |
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.
Q&A For Generex Biotechnology Corporation Stock
What is a current GB8A.SG stock price?
Generex Biotechnology Corporation GB8A.SG stock price today per share is 0.02 EUR.
How to purchase Generex Biotechnology Corporation stock?
You can buy GB8A.SG shares on the Stuttgart exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Generex Biotechnology Corporation?
The stock symbol or ticker of Generex Biotechnology Corporation is GB8A.SG.
How many shares does Generex Biotechnology Corporation have in circulation?
The max supply of Generex Biotechnology Corporation shares is 118.45M.
What is Generex Biotechnology Corporation Price to Earnings Ratio (PE Ratio)?
Generex Biotechnology Corporation PE Ratio is now.
What was Generex Biotechnology Corporation earnings per share over the trailing 12 months (TTM)?
Generex Biotechnology Corporation EPS is -0.354 EUR over the trailing 12 months.